- Home
- NLSP vs ABEO Comparison
NLSP vs ABEO Comparison
Compare NLSP & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- ABEO
- Stock Information
- Founded
- NLSP 2015
- ABEO N/A
- Country
- NLSP Switzerland
- ABEO United States
- Employees
- NLSP N/A
- ABEO N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- ABEO Health Care
- Exchange
- NLSP Nasdaq
- ABEO Nasdaq
- Market Cap
- NLSP 243.8M
- ABEO 243.9M
- IPO Year
- NLSP 2021
- ABEO 1980
- Fundamental
- Price
- NLSP $5.30
- ABEO $6.55
- Analyst Decision
- NLSP
- ABEO Strong Buy
- Analyst Count
- NLSP 0
- ABEO 3
- Target Price
- NLSP N/A
- ABEO $18.00
- AVG Volume (30 Days)
- NLSP 26.9K
- ABEO 263.3K
- Earning Date
- NLSP 10-18-2024
- ABEO 11-11-2024
- Dividend Yield
- NLSP N/A
- ABEO N/A
- EPS Growth
- NLSP N/A
- ABEO N/A
- EPS
- NLSP N/A
- ABEO N/A
- Revenue
- NLSP N/A
- ABEO N/A
- Revenue This Year
- NLSP N/A
- ABEO N/A
- Revenue Next Year
- NLSP N/A
- ABEO $7,097.06
- P/E Ratio
- NLSP N/A
- ABEO N/A
- Revenue Growth
- NLSP N/A
- ABEO 147.52
- 52 Week Low
- NLSP $4.08
- ABEO $3.05
- 52 Week High
- NLSP $40.60
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- NLSP 45.46
- ABEO 64.53
- Support Level
- NLSP $4.72
- ABEO $6.39
- Resistance Level
- NLSP $5.50
- ABEO $6.74
- Average True Range (ATR)
- NLSP 0.61
- ABEO 0.31
- MACD
- NLSP 0.05
- ABEO 0.03
- Stochastic Oscillator
- NLSP 41.67
- ABEO 70.95
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.